{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(1)"],"submitter":["Kallunki P"],"funding":["H. Lundbeck A/S","Genmab"],"pubmed_abstract":["Amlenetug (Lu AF82422) is a human monoclonal antibody targeting α-synuclein in clinical development for multiple system atrophy. We describe a series of studies that characterize its functional properties and supported its selection as a viable clinical candidate. Amlenetug inhibits seeding induced in mouse primary neurons by various α-synuclein fibrillar assemblies and by aggregates isolated from MSA brain homogenate. In vivo, both co-injection of amlenetug with α-synuclein assemblies in mouse brain and peripheral administration inhibit α-synuclein seeding. Amlenetug inhibits uptake of α-synuclein seeds as well as accumulation of C-terminal truncated α-synuclein seeds and demonstrates binding to monomeric, aggregated, and truncated forms of human α-synuclein. The epitope of amlenetug was "],"journal":["NPJ Parkinson's disease"],"pagination":["132"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12098740"],"repository":["biostudies-literature"],"pubmed_title":["Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies."],"pmcid":["PMC12098740"],"pubmed_authors":["Fog K","Christensen S","Bjerregaard-Andersen K","Egebjerg J","Sotty F","Jensen A","Parren PWHI","Nyegaard S","Ambjorn M","Damlund DSM","Olsen LR","David L","Soderberg JN","Bergstrom AL","Rademaker R","Satijn D","Kallunki P","Willen K","Krogh BO","Eriksen TT","Malik I","Pedersen LO","Harndahl MN","Lubas M","van den Brink EN","Andersen KJ","Cholak E","Wulff-Larsen PG","Vergo S","Vink T","Buur L","Stavenhagen JB"],"additional_accession":[]},"is_claimable":false,"name":"Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.","description":"Amlenetug (Lu AF82422) is a human monoclonal antibody targeting α-synuclein in clinical development for multiple system atrophy. We describe a series of studies that characterize its functional properties and supported its selection as a viable clinical candidate. Amlenetug inhibits seeding induced in mouse primary neurons by various α-synuclein fibrillar assemblies and by aggregates isolated from MSA brain homogenate. In vivo, both co-injection of amlenetug with α-synuclein assemblies in mouse brain and peripheral administration inhibit α-synuclein seeding. Amlenetug inhibits uptake of α-synuclein seeds as well as accumulation of C-terminal truncated α-synuclein seeds and demonstrates binding to monomeric, aggregated, and truncated forms of human α-synuclein. The epitope of amlenetug was ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2026-06-02T00:30:11.824Z","creation":"2026-05-24T03:07:06.046Z"},"accession":"S-EPMC12098740","cross_references":{"pubmed":["40404755"],"doi":["10.1038/s41531-024-00849-1"]}}